Kringle Pharma (TSE:4884) Operating Margin %: -1,736.02% (As of Mar. 2026)


TSE:4884 Kringle Pharma Inc TSE:4884
40 GF Score
Price 円318.00
GF Value 円497.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Operating Margin %?

Kringle Pharma TSE:4884 +2.91% 40 Operating Margin % is -1,736.02% as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 40/100 and a GF Value™ of 円497.82 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Kringle Pharma ranks worse than 80.3% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Kringle Pharma's Operating Income for the three months ended in Mar. 2026 was 円-315.37 Mil. Kringle Pharma's Revenue for the three months ended in Mar. 2026 was 円18.17 Mil. Therefore, Kringle Pharma's Operating Margin % for the quarter that ended in Mar. 2026 was -1,736.02%.

Warning Sign:

Kringle Pharma Inc operating margin has been in a 5-year decline. The average rate of decline per year is -113.1%.

The historical rank and industry rank for Kringle Pharma's Operating Margin % or its related term are showing as below:

TSE:4884' s Operating Margin % Range Over the Past 10 Years
Min: -1283.41   Med: -572.69   Max: -36.7
Current: -1250.01


TSE:4884's Operating Margin % is ranked worse than
80.3% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs TSE:4884: -1250.01

Kringle Pharma's 5-Year Average Operating Margin % Growth Rate was -113.10% per year.

Kringle Pharma's Operating Income for the three months ended in Mar. 2026 was 円-315.37 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was 円-912.79 Mil.


Kringle Pharma  (TSE:4884) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Kringle Pharma Operating Margin % Related Terms


Kringle Pharma Operating Margin % Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Operating Margin % Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Operating Margin %
Get a 7-Day Free Trial -123.51 -108.76 -1,283.41 -1,021.87 -1,259.37

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1,261.24 -932.95 -1,076.51 -1,736.02

TSE:4884 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Kringle Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kringle Pharma Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kringle Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Kringle Pharma's Operating Margin % falls into.


TSE:4884
40GF Score
Kringle Pharma Inc TSE:4884
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Kringle Pharma's Operating Margin % for the fiscal year that ended in Sep. 2025 is calculated as

Operating Margin %=Operating Income (A: Sep. 2025 ) / Revenue (A: Sep. 2025 )
=-909.452 / 72.215
=-1,259.37 %

Kringle Pharma's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-315.366 / 18.166
=-1,736.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -1,736.02% mean?
Kringle Pharma (TSE:4884) has a Operating Margin % of -1,736.02% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Kringle Pharma and its competitors. According to the industry distribution chart, Kringle Pharma ranks #758 out of 944 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Kringle Pharma's Operating Margin % too high?
Kringle Pharma's current Operating Margin % is -1,736.02%. Based on the distribution chart, Kringle Pharma ranks #758 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kringle Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #758 out of 944 companies for Operating Margin %. This places Kringle Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Operating Margin % is -1,736.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円497.82, compared to a current price of 円318.00 — trading 36.1% below its estimated fair value. The current Operating Margin % is -1,736.02%. Kringle Pharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Operating Margin % is -1,736.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円318.00 is trading 36.1% below its estimated GF Value™ of 円497.82. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • Operating Margin %: -1,736.02%
  • GF Value™: 円497.82 vs. price of 円318.00 (36.1% below fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
40GF Score

Get the complete analysis for TSE:4884

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円318.00
Price
円497.82
GF Value